Sir, Complement is a major mediator of glomerular inflammation in several form of glomerulonephritis such as lupus nephritis, membranous nephritis, anti-GBM nephritis, or IgA nephropathy. Activation of the terminal pathway leads to cleavage of C5 and release of the potent anaphylatoxin C5a. C5a and its catabolite C5a(desArg) mediate their potent proinflammatory effects through binding to the C5a receptor CD88. The G-protein-coupled receptor is expressed mainly by cells of myeloid origin such as macrophages and neutrophils. CD88 expression has also been reported in lung, liver, and brain tissue [1] . A recent report describes expression of CD88 on cultured human mesangial cells. Stimulation of the receptor caused mildly enhanced proliferation and synthesis of MCP-1 and platelet-derived growth factor (PDGF ) [2] . The C5a receptor has also been described on proximal tubular cells and macrophages in normal renal tissue [3] .
These reports prompted us to investigate CD88 expression in human renal diseases, mainly glomerulonephritis. Thirtyone consecutive renal biopsies and one normal control tissue from a kidney removed for renal-cell carcinoma were investigated. The diagnostic groups are shown in Table 1 . Of the four patients with rapidly progressive glomerulonephritis (RPGN ), two had anti-GBM nephritis, one an antineutrophilic cytoplasmic antibody (ANCA)-associated nephritis, and one suffered from Henoch-Schö nlein purpura. The biopsies were investigated using the direct immunofluorescence method. Five-micrometre-thick acetone-fixed cryostat section were incubated with two well-characterized monoclonal anti-CD88 antibodies P12/11 (2 mg/ml ) and D12/1 (4 mg/ml ) for 30 min [3] . In addition, a mouse monoclonal (a) (b) anti-leukocyte common antigen-antibody was used to stain rabbit-anti-mouse immunoglobulin antibody was applied.
In normal renal tissue we found CD88 on proximal tubular epithelial cells with some predominance on the basolateral were CD88 positive. No staining of intrinsic glomerular cells membrane ( Figure 1a ). In addition a few interstitial cells was observed in normal renal tissue or in all cases of glomerulonephritis or interstitial nephritis. Tubular staining was unaltered in most biopsies and reduced only in areas of 
Treatment of a case of severe mercuric salt overdose with DMPS (dimercapo-1-propane sulphonate) and continuous haemofiltration
Sir, We present the clinical course of a man after deliberately taking inorganic mercury salt. The initial blood mercury level was 5200 mg/l (normal <5 mg/l ), which reduced to 3600 mg/l after the first HD Case. A 48-year-old man had deliberately taken approximately 10 ml of inorganic mercury salt. Vomiting and abdom-treatment ( Table 1) . Daily HD lasting 4-7 h was carried out using the same type of dialyser, except for the fifth treatment inal pain began within an hour of ingestion. At 6 h, haemoglobin (Hb) was 19.4 g/dl, white cell count ( WCC ) session when a larger dialyser (F10, Fresenius) was used. It became clear that overall HD treatment had little effect on 16.6×109/l, platelets 259×109/l, serum potassium 4.8 mmol/l, urea 5.7 mmol/l, creatinine 126 mmol/l, bilirubin mercury removal, with dialysate mercury levels ranging from 0 to 75 mg/l. Treatment was changed to continuous venoven-46 mmol/l, alanine transaminase 39 IU/l, amylase 78 IU/l. This was followed over a 24-h period by onset of haematem-ous haemofiltration (CVVH ) with 6-hourly i.v. DMPS, followed by two sessions of (3 litres) plasma exchange (PE). esis, haemoptysis, hypovolaemic shock and oligoanuric renal failure. Serum creatinine rose to 329 mmol/l, urea 15 mmol/l, The patient underwent a total of 51 h of CVVH using a high-flux polysulphone membrane ( Ultraflux AV 400, potassium unchanged, bilirubin 53 mmol/l, alanine transaminase 1149 IU/l, amylase 165 IU/l, Hb unchanged, WCC Fresenius) and a filtration rate of 1 l/h. A break in the treatment occurred after 32 h because of clotting of the filter. 41.1×109/l, platelets 218×109/l. Arterial blood gas analysis showed a pH of 7.29, PO 2 13.2 kPa, pCO 2 4.6 kPa, HCO 3 During this 32 h of treatment, 8735 mg of mercury were recovered from the ultrafiltrate and the patient's blood 16 mmol/l, base excess of −9. Haemodialysis (HD) was commenced.
mercury level reduced from 5600 to 2300 mg/l. During the next 19 h of treatment, the blood mercury level fell further Dimercaprol (150 mg), a chelating agent for mercury overdose was given intramuscularly 1 h before the first to 990 mg/l. Two sessions of PE were undertaken after the CVVH. The blood mercury level fell from 850 to 610 mg/l dialysis treatment. Twenty minutes after administration, the patient developed transient severe pain in the chest and after the first session of PE. The plasma filtrate sample contained 5300 mg/l of mercury. abdomen, thought to be a reaction to dimercaprol. The patient underwent a 6-h HD session using a low-flux polysul-
The patient began to pass urine on day 10. A final HD treatment was necessary on day 13 for hyperkalaemia and phone membrane of 1.3 m2 surface area (F7, Fresenius Medical Care, Germany) at a blood flow rate of 200 ml/min rising serum urea and creatinine. Normal serum creatinine was achieved by day 45. Gastrointestinal bleeding continued and a dialysate flow rate of 500 ml/min. Samples of blood and dialysis fluid were taken at regular intervals for deter-for a total of 4 weeks in spite of treatment with sulcrafate, proton pump inhibitor, tranexamic acid and aprotinin. The mination of whole-blood mercury concentration by cold vapour atomic absorption spectrometry.
patient required a total of 58 units of blood transfusion. In view of the possible reaction to dimercaprol, the patient was given intravenous DMPS (dimercapo-1-propane sulph-Comment. Inorganic mercury can induce an autoimmune glomerulonephritis, with an ingestion of 1-4 g of inorganic onate) prior to the second HD treatment 10 h later. The dose used was 250 mg, 6-hourly for 7 days, then 8-hourly mercuric salt reported as lethal [1] . Mercuric ion binds to the sulphydryl group of proteins and causes necrosis to the for 1 day, then 12-hourly for 8 days, then once a day for 7 days. mucosa of the gastrointestinal tract, leading to gastrointesti-
